Payment overview · 2025
General Payments
$53.37
3 reported records · 3 companies
Healthcare provider profile · identity verified
John G Fox, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEARWATER, FL · NPI 1164474086
Verified facts
What the public records show
CMS Open Payments records show John G Fox, MD received $53.37 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.44 | 36.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.93 | 33.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.00 | 30.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $53.37 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
95 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 715 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 536 | 148 |
| Alprazolam | Alprazolam | 524 | 99 |
| Losartan Potassium | Losartan Potassium | 464 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 112 |
| Lisinopril | Lisinopril | 358 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 321 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 80 |
| Azithromycin | Azithromycin | 294 | 160 |
| Omeprazole | Omeprazole | 294 | 83 |
| Simvastatin | Simvastatin | 291 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 235 | 52 |
| Allopurinol | Allopurinol | 229 | 67 |
| Gabapentin | Gabapentin | 218 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 207 | 51 |
| Metformin Hcl | Metformin Hcl | 207 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 55 |
| Tramadol Hcl | Tramadol Hcl | 195 | 45 |
| Trazodone Hcl | Trazodone Hcl | 179 | 61 |
| Lorazepam | Lorazepam | 172 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 160 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 46 |
| Eliquis | Apixaban | 156 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 47 |
| Furosemide | Furosemide | 137 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 33 |
| Sertraline Hcl | Sertraline Hcl | 131 | 36 |
| Glimepiride | Glimepiride | 130 | 36 |
| Methylprednisolone | Methylprednisolone | 129 | 87 |
| Meloxicam | Meloxicam | 127 | 38 |
| Carvedilol | Carvedilol | 125 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 37 |
| Donepezil Hcl | Donepezil Hcl | 97 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 65 |
| Synthroid | Levothyroxine Sodium | 95 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 37 |
| Montelukast Sodium | Montelukast Sodium | 91 | 29 |
| Irbesartan | Irbesartan | 87 | 22 |
| Atenolol | Atenolol | 85 | 25 |
| Temazepam | Temazepam | 81 | 17 |
| Diazepam | Diazepam | 80 | 14 |
| Amoxicillin | Amoxicillin | 78 | 38 |
| Valsartan | Valsartan | 78 | 22 |
| Xarelto | Rivaroxaban | 75 | 15 |
| Jardiance | Empagliflozin | 70 | 16 |
| Clonazepam | Clonazepam | 68 | 15 |
| Potassium Chloride | Potassium Chloride | 68 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 24 |
| Celecoxib | Celecoxib | 63 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 41 |
| Myrbetriq | Mirabegron | 59 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 46 |
| Paxlovid | Nirmatrelvir/Ritonavir | 57 | 55 |
| Cefdinir | Cefdinir | 55 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | 15 |
| Famotidine | Famotidine | 53 | 11 |
| Terazosin Hcl | Terazosin Hcl | 53 | 16 |
| Fluconazole | Fluconazole | 52 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 38 |
| Spironolactone | Spironolactone | 50 | 17 |
| Valacyclovir | Valacyclovir Hcl | 48 | 21 |
| Ezetimibe | Ezetimibe | 46 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 15 |
| Cephalexin | Cephalexin | 44 | 29 |
| Midodrine Hcl | Midodrine Hcl | 44 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 14 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 12 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | 12 |
| Ibuprofen | Ibuprofen | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 15 |
| Finasteride | Finasteride | 40 | 11 |
| Nystatin | Nystatin | 40 | 23 |
| Glipizide | Glipizide | 39 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | 11 |
| Calcitriol | Calcitriol | 37 | suppressed |
| Prednisone | Prednisone | 37 | 25 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | 13 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | 14 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | 12 |
| Nitroglycerin | Nitroglycerin | 27 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 12 |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Benzonatate | Benzonatate | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Ergotamine-Caffeine | Ergotamine Tartrate/Caffeine | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53.37 · 3 records | ABBVIE INC. | AIRSUPRA, Ozempic, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error